Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Share this content:
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Sponsor and Collaborators
Tolera Therapeutics, Inc

Contact
Leslie O'Toole, RN
269-585-2100 ext 2111
lotoole@tolera.com

Principal Investigator
Stuart Flechner, MD
The Cleveland Clinic

ClinicalTrials.gov Identifier
NCT01154387
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters